Ther-O-02 - The COBALT-LYM study of CTX130: a phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-Cas9–engineered CAR T cells in patients with relapsed/refractory (R/R) T-cell malignancies.
Radiation Therapy for Primary Cutaneous Gamma Delta Lymphoma Prior to Stem Cell Transplantation.
Autorzy:
Wu YF; Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA. Skinner L; Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA. Lewis J; Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA. KhodadoustMS; Internal Medicine, Medical Oncology, Stanford University School of Medicine, Stanford, CA, USA. Kim YH; Dermatology, Stanford University School of Medicine, Stanford, CA, USA. Kwong BY; Dermatology, Stanford University School of Medicine, Stanford, CA, USA. Weng WK; Stem Cell Transplantation, Stanford University School of Medicine, Stanford, CA, USA. Hoppe RT; Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA. Sodji Q; Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA. Hui C; Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA. Kastelowitz N; Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA. Fernandez-Pol S; Pathology, Stanford University School of Medicine, Stanford, CA, USA. Hiniker SM; School of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Pokaż więcej
Źródło:
Cancer investigation [Cancer Invest] 2023 Jan 31, pp. 1-8. Date of Electronic Publication: 2023 Jan 31.
Low-dose total skin electron beam therapy for refractory cutaneous CD30 positive lymphoproliferative disorders.
Autorzy:
Panjwani N; Department of Radiation Oncology, Stanford University, Stanford, CA, USA. Yoo CH; Department of Radiation Oncology, Stanford University, Stanford, CA, USA. Wang E; Department of Dermatology, Stanford University, Stanford, CA, USA. KhodadoustMS; Department of Oncology, Stanford University, Stanford, CA, USA. Kim YH; Department of Dermatology, Stanford University, Stanford, CA, USA. Hoppe RT; Department of Radiation Oncology, Stanford University, Stanford, CA, USA. Hiniker SM; Department of Radiation Oncology, Stanford University, Stanford, CA, USA.
Cutaneous T-cell lymphomas with pathogenic somatic mutations and absence of detectable clonal T-cell receptor gene rearrangement: two case reports.
Autorzy:
Rojansky R; Department of Pathology, Stanford Medicine, Stanford, CA, 94305, USA. Fernandez-Pol S; Department of Pathology, Stanford Medicine, Stanford, CA, 94305, USA. Wang E; Department of Dermatology, Stanford Medicine, Stanford, CA, 94305, USA. Rieger KE; Department of Pathology, Stanford Medicine, Stanford, CA, 94305, USA.; Department of Dermatology, Stanford Medicine, Stanford, CA, 94305, USA. Novoa RA; Department of Pathology, Stanford Medicine, Stanford, CA, 94305, USA.; Department of Dermatology, Stanford Medicine, Stanford, CA, 94305, USA. Zehnder JL; Department of Pathology, Stanford Medicine, Stanford, CA, 94305, USA.; Division of Hematology, Department of Medicine, Stanford Medicine, Stanford, CA, 94305, USA. Kunder CA; Department of Pathology, Stanford Medicine, Stanford, CA, 94305, USA. Kim YH; Department of Dermatology, Stanford Medicine, Stanford, CA, 94305, USA.; Division of Oncology, Department of Medicine, Stanford Medicine, Stanford, CA, 94305, USA. KhodadoustMS; Department of Dermatology, Stanford Medicine, Stanford, CA, 94305, USA.; Division of Oncology, Department of Medicine, Stanford Medicine, Stanford, CA, 94305, USA. Brown RA; Department of Pathology, Stanford Medicine, Stanford, CA, 94305, USA. .; Department of Dermatology, Stanford Medicine, Stanford, CA, 94305, USA. .; Department of Pathology, Veterans Affairs Palo Alto Health Care System, 3375 Hillview Ave, Room 1821, Palo Alto, CA, 94304-1204, USA. .
Pokaż więcej
Źródło:
Diagnostic pathology [Diagn Pathol] 2020 Sep 28; Vol. 15 (1), pp. 122. Date of Electronic Publication: 2020 Sep 28.
Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin.
Autorzy:
Narayan R; Department of Medicine, Division of Hematology, Stanford University, Stanford, CA, United States of America. Olsson N; Department of Chemical and Systems Biology, Stanford University, Stanford, CA, United States of America. Wagar LE; Department of Microbiology & Immunology, Stanford University, Stanford, CA, United States of America. Medeiros BC; Department of Medicine, Division of Hematology, Stanford University, Stanford, CA, United States of America. Meyer E; Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University, Stanford, CA, United States of America. Czerwinski D; Department of Medicine, Division of Oncology, Stanford University, Stanford, CA, United States of America. KhodadoustMS; Department of Medicine, Division of Oncology, Stanford University, Stanford, CA, United States of America. Zhang L; Department of Chemical and Systems Biology, Stanford University, Stanford, CA, United States of America. Schultz L; Department of Pediatrics, Division of Hematology/Oncology, Stanford University, Stanford, CA, United States of America. Davis MM; Department of Microbiology & Immunology, Stanford University, Stanford, CA, United States of America.; Howard Hughes Medical Institute, Stanford University, Stanford, CA, United States of America. Elias JE; Department of Chemical and Systems Biology, Stanford University, Stanford, CA, United States of America. Levy R; Department of Medicine, Division of Oncology, Stanford University, Stanford, CA, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2019 Jul 10; Vol. 14 (7), pp. e0219547. Date of Electronic Publication: 2019 Jul 10 (Print Publication: 2019).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
